Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia

Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin, is approved for the treatment of newly-diagnosed CD33 + AML in adults and children ≥ 1 month old, and relapsed or refractory CD33 + AML in adults and children ≥ 2 years o...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Hematol Oncol
Main Authors: Cortes, Jorge E., de Lima, Marcos, Dombret, Hervé, Estey, Elihu H., Giralt, Sergio A., Montesinos, Pau, Röllig, Christoph, Venditti, Adriano, Wang, Eunice S.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2020
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7559451/
https://ncbi.nlm.nih.gov/pubmed/33059764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00975-2
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki